Telik Reports Positive Interim Results of Telcyta With Cisplatin

Telik has reported positive interim data from a multicenter Phase I/IIa clinical study evaluating Telcyta (TLK286) in combination with cisplatin in the first-line treatment of advanced non-small cell lung cancer.

In the trial, a 36 percent objective response rate and an 86 percent disease stabilization rate were observed in the evaluable patients at the time of the interim analysis. At the time of interim analysis, a total of 47 patients were enrolled in the trial. Of these, 22 patients treated at the Phase IIa dose (Telcyta at 1,000 mg/m2 and cisplatin 75 mg/m2) were evaluable for efficacy. There were eight partial responses and 11 patients with stable disease. Objective responses were observed in subtypes including squamous cell, large cell, BAC and adenocarcinoma, as well as in males and females and current, former and never smokers.

Overall, the Telcyta plus cisplatin combination was generally well-tolerated, without unanticipated toxicities. Median survival has not yet been reached. Enrollment in the trial is now complete.